Patient-Reported Outcomes Measurement Information System

Two Research Leaders from CHOP Elected to National Academy of Medicine

Retrieved on: 
Monday, October 9, 2023

PHILADELPHIA, Oct. 9, 2023 /PRNewswire/ -- Two renowned experts from Children's Hospital of Philadelphia (CHOP) have been elected to the National Academy of Medicine (NAM), effective October 1, 2023. CHOP Chief Scientific Officer Susan Furth, MD, PhD, and CHOP pediatrician and PEDSnet founder Christopher B. Forrest, MD, PhD, have both been recognized for outstanding professional achievement. An election to NAM is considered one of the highest honors in health and medicine.

Key Points: 
  • CHOP Chief Scientific Officer Susan Furth , MD, PhD, and CHOP pediatrician and PEDSnet founder Christopher B. Forrest , MD, PhD, have both been recognized for outstanding professional achievement.
  • In addition to her nephrology research, Dr. Furth is Chief Scientific Officer and Executive Vice President at CHOP, where she oversees the CHOP Research Institute and its more than 1,000 investigators and 2,600 employees.
  • He is the Director and Founder of PEDSnet , a national pediatric learning health system, which is one of the PCORnet Clinical Research Networks.
  • Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, the NAM addresses critical issues in health, science, medicine, and related policy.

Spinal Simplicity chooses OBERD for their Minuteman Registry

Retrieved on: 
Thursday, August 3, 2023

Spinal Simplicity gives clients the option to capture Patient-Reported Outcomes Measures and clinical data through OBERD.

Key Points: 
  • Spinal Simplicity gives clients the option to capture Patient-Reported Outcomes Measures and clinical data through OBERD.
  • Data captured through the Spinal Simplicity Registry enables deep dive analysis on the efficacy and effectiveness of the Minuteman MIS Fusion Plate.
  • "Partnering with a forward-thinking company like Spinal Simplicity brings the importance of patient data to light," said Ali Hussam, PhD, CEO and Co-Founder of OBERD.
  • For further information, contact Blake McWilliams, VP of Sales & Marketing, OBERD at [email protected] or Parker Snedden, Director of Strategic Marketing, Spinal Simplicity at [email protected] .

Signant's Novel Electronic PROMIS CAT Assessment Enhances Patient-Centric Drug Development

Retrieved on: 
Wednesday, February 8, 2023

In contrast, PROMIS CATs use a dynamic approach that aims to measure concepts, such as fatigue or physical functioning, with fewer questions while maintaining precision.

Key Points: 
  • In contrast, PROMIS CATs use a dynamic approach that aims to measure concepts, such as fatigue or physical functioning, with fewer questions while maintaining precision.
  • Fully hosted by Signant Health, PROMIS CATs can be rapidly implemented and incorporated seamlessly into the company's eCOA solution alongside conventional PROMs.
  • "We're excited to build on our pioneering heritage of eCOA innovations with the release of this unique PROMIS CAT implementation, an important leap forward in patient-centric clinical development," said Sanjiv Waghmare, Signant's chief product officer.
  • State-of-the-science electronic PROMIS CATs can be delivered seamlessly through the same eCOA application patients use to complete conventional PROMs, and includes scientific consultation and support by Signant's clinical and digital health science experts.

Signant's Novel Electronic PROMIS CAT Assessment Enhances Patient-Centric Drug Development

Retrieved on: 
Wednesday, February 8, 2023

In contrast, PROMIS CATs use a dynamic approach that aims to measure concepts, such as fatigue or physical functioning, with fewer questions while maintaining precision.

Key Points: 
  • In contrast, PROMIS CATs use a dynamic approach that aims to measure concepts, such as fatigue or physical functioning, with fewer questions while maintaining precision.
  • Fully hosted by Signant Health, PROMIS CATs can be rapidly implemented and incorporated seamlessly into the company's eCOA solution alongside conventional PROMs.
  • "We're excited to build on our pioneering heritage of eCOA innovations with the release of this unique PROMIS CAT implementation, an important leap forward in patient-centric clinical development," said Sanjiv Waghmare, Signant's chief product officer.
  • State-of-the-science electronic PROMIS CATs can be delivered seamlessly through the same eCOA application patients use to complete conventional PROMs, and includes scientific consultation and support by Signant's clinical and digital health science experts.

Study Featured at ACR Convergence 2022 Demonstrates Strength of Adhera Health's Rheumatology Digital Program in Supporting Rheumatic and Musculoskeletal Patients Self-Management and ePROs Monitoring

Retrieved on: 
Tuesday, November 8, 2022

With support from AbbVie and the Spanish Society of Rheumatology, the six-month clinical study included 46 patients, of whom 22 had RA and 24 SpA.

Key Points: 
  • With support from AbbVie and the Spanish Society of Rheumatology, the six-month clinical study included 46 patients, of whom 22 had RA and 24 SpA.
  • Results from the study demonstrate that the Adhera Rheumatology Digital Program, built using the Adhera Precision Digital Companion platform, has a positive impact in supporting RA and SpA patients' self-management and the monitoring of ePROs.
  • "Patients with rheumatic and musculoskeletal diseases require frequent, personalized monitoring, self-management support, and treatment.
  • Patients participating in the study used a mobile app where they were asked to report disease-specific ePROs on a regular basis.

Study Shows Adolescent Athletes Able to Rapidly Return to Sports Following Scoliosis Surgery

Retrieved on: 
Monday, October 10, 2022

"Safe return to sports and other physical activities has become commonplace among patients with idiopathic scoliosis who undergo spine fusion surgery.

Key Points: 
  • "Safe return to sports and other physical activities has become commonplace among patients with idiopathic scoliosis who undergo spine fusion surgery.
  • However, before this study there was no prospective data regarding timing for safely returning to sport."
  • The study showed when athletes were released to unrestricted activity at four to eight weeks, athletes quickly return to baseline levels of sports performance with over half achieving this metric by three months.
  • Athletes completed preoperative sports performance and Patient Reported Outcomes Measurement Information System (PROMIS) physical activity, pain interference and depressive symptoms questionnaires.

New 'Voice of the Patient' Report Highlights Unmet Needs of Asthma in Childhood

Retrieved on: 
Tuesday, September 20, 2022

The Voice of the Patient Report on Asthma in Childhood summarizes findings from the Little Airways, Big Voices initiative and identifies what is important to people who live with and manage asthma in childhood.

Key Points: 
  • The Voice of the Patient Report on Asthma in Childhood summarizes findings from the Little Airways, Big Voices initiative and identifies what is important to people who live with and manage asthma in childhood.
  • The Voice of the Patient report explores current and future approaches to treating childhood asthma.
  • We published the Voice of the Patient Report on Asthma in Childhood to inform the development and regulatory review of potential new asthma treatments that are meaningful to children with asthma.
  • There are still unmet needs in prevention, diagnosis, treatment, and progression of asthma in childhood.

Treace Announces Updated ALIGN3D™ Data at the 2022 AOFAS Annual Meeting

Retrieved on: 
Tuesday, September 13, 2022

John T. Treace, CEO, Founder and Board Member of Treace said, Interim data readouts from our ongoing ALIGN3D clinical study continue to demonstrate sustained, successful procedural and patient outcomes on additional patients followed through 12-, 24- and 36-months post-surgery.

Key Points: 
  • John T. Treace, CEO, Founder and Board Member of Treace said, Interim data readouts from our ongoing ALIGN3D clinical study continue to demonstrate sustained, successful procedural and patient outcomes on additional patients followed through 12-, 24- and 36-months post-surgery.
  • The audio poster, which includes additional details, can be accessed by meeting attendees on a kiosk at the Annual Meeting or on the mobile app.
  • The updated data is also available on the Treace Medical website.
  • The AOFAS Annual Meeting is the premier event for foot and ankle education, offering presentations from renowned speakers, special interest forums and the latest products and technology.

Westat to Continue Support of NCI's Cancer Trials Support Unit (CTSU)

Retrieved on: 
Tuesday, August 30, 2022

ROCKVILLE, Md., Aug. 30, 2022 /PRNewswire-PRWeb/ -- The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has awarded the Cancer Trials Support Unit (CTSU) IDIQ contract 75N91022D00009 to Westat for a 10-year ordering period (if all options are exercised). This project has been funded in whole or in part with federal funds from the NCI, NIH, Department of Health and Human Services (HHS).

Key Points: 
  • Westat will partner with NCI, providing quality service and value through finding efficiencies, stakeholder collaboration, and innovative solutions to support the transformation of the clinical trials enterprise.
  • ROCKVILLE, Md., Aug. 30, 2022 /PRNewswire-PRWeb/ -- The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has awarded the Cancer Trials Support Unit (CTSU) IDIQ contract 75N91022D00009 to Westat for a 10-year ordering period (if all options are exercised).
  • Our Westat team looks forward to working with the NCI cancer research program to carry out and grow its mission," notes Nancy Dianis, R.N., M.S.
  • Westat provides innovative professional services support to clients in addressing challenges to improve outcomes in health, education, social policy, and transportation.

Survey on Sexual Health Among Women with Lung Cancer Reveals High Levels of Sexual Dysfunction

Retrieved on: 
Tuesday, August 9, 2022

(Vienna, Austria)--According to survey data reported today, sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity. The survey results from the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study were reported today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

Key Points: 
  • According to survey data reported today, sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity.
  • (Vienna, Austria)--According to survey data reported today, sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity.
  • The survey results from the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study were reported today at the IASLC World Conference on Lung Cancer 2022 in Vienna.
  • "We report the results of the SHAWL study, the largest study to date evaluating sexual dysfunction in women with lung cancer."